Cytokine regulation networks in the cancer microenvironment

Frontiers in Bioscience

Volumn 13, Issue 16, 2008, Pages 6255-6268

  Sheu, Bor Ching ^a   Chang, Wen Chun ^a   Cheng, Chieh Yang ^a   Lin, Ho Hsiung ^a   Chang, Daw Yuan ^a   Huang, Su Cheng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cancer; Cytokine; Immune regulation; Review; T cell

Indexed keywords

CXCL12 PROTEIN, HUMAN; CYTOKINE; INTERFERON; STROMAL CELL DERIVED FACTOR 1; TNFSF10 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

DENDRITIC CELL; HUMAN; IMMUNOLOGY; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

CHEMOKINE CXCL12; CYTOKINES; DENDRITIC CELLS; HUMANS; INTERFERONS; NEOPLASMS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFORMING GROWTH FACTOR BETA;

EID: 52049108902     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: None     Document Type: Article

References (139)

1. Aznavoorian S, M.L. Stracke, H.C. Krutzsch, E. Schiffmann & L.A. Liotta: Signal transduction forchemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol 110, 1427-1438 (1999)
2. Liotta L. A, K. Tryggvason, S. Garbisa, I. Hart, C. M. Foltz & S. Shafie: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284, 67-68 (1980) (Pubitemid 10098769)
3. Nakajima M, K. Morikawa, A. Fabra, C. D. Bucana & I. J. Fidler: Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst 82, 1890-1898 (1990)
4. Liotta L. A & E. C. Kohn: The microenvironment of the tumour-host interface. Nature 411, 375-379 (2001)
5. Fox J.G & T.C. Wang: Inflammation, atrophy, and gastric cancer. J Clin Invest 117, 60-69 (2007) (Pubitemid 46048450)
6. de Visser K.E, A. Eichten & L.M. Coussens: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6, 24-37 (2006) (Pubitemid 43053650)
7. Karin M: Nuclear factor-κB in cancer development and progression. Nature 441, 431-436 (2006) (Pubitemid 44050137)
8. Luo J.L, H. Kamata & M. Karin: IKK/ NF-κB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 115, 2625-2632 (2005) (Pubitemid 41434385)
9. Wan-Wan L & K. Michael: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117, 1175-1183 (2007)
10. Dunn G.P, L.J. Old & R.D. Schreiber: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148 (2004) (Pubitemid 39094044)
11. Restifo N.P, P.A. Antony, S.E. Finkelstein, W.W. Leitner, D.P. Surman & M.R. Theoret: Assumptions of the tumor 'escape' hypothesis. Semin Cancer Biol 12, 81-86 (2002) (Pubitemid 34087902)
12. Kaporis H.G, E. Guttman-Yassky, M.A. Lowes, A.S. Haider, J. Fuentes-Duculan, K. Darabi, J. Whynot-Ertelt, A. Khatcherian, I. Cardinale, I. Novitskaya, J.G. Krueger, J.A. Carucci: Human Basal Cell Carcinoma Is Associated with Foxp3+ T cells in a Th2 Dominant Microenvironment. J Invest Dermatol 127, 2391-2398 (2007) (Pubitemid 47619759)
13. Cui G, R. Goll, T. Olsen, S.E. Steigen, A. Husebekk, B. Vonen & J. Florholmen: Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. CancerImmunol Immunother 56, 985-995 (2007) (Pubitemid 46675303)
14. Murakami H, H. Ogawara & H. Hiroshi: Th1/Th2 cells in patients with multiple myeloma. Hematology 9, 41-45 (2004) (Pubitemid 38256010)
15. Bierie B & H.L. Moses: Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6, 506-520 (2006) (Pubitemid 43980540)
16. Bierie B & H.L. Moses: TGF-beta and cancer. CytokineGrowth Factor Rev 17, 29-40 (2006)
17. Cheng N, N.A. Bhowmick, A. Chytil, A.E. Gorksa, K.A. Brown, R. Muraoka, C.L. Arteaga, E.G. Neilson, S.W. Hayward & H.L. Moses: Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP-and HGF-mediated signaling networks. Oncogene 24, 5053-5068 (2005) (Pubitemid 41129083)
18. Kim B.G, C. Li, W. Qiao, M. Mamura, B. Kasperczak, M. Anver, L.Wolfraim, S. Hong, E. Mushinski, M. Potter, S.J. Kim, X.Y. Fu, C. Deng & J.J. Letterio. Smad4 signaling in T cells is required for suppression of gastrointestinal cancer. Nature 441, 1015-1019 (2006) (Pubitemid 43980359)
19. Verona E.V, A.G. Elkahloun, J. Yang, A. Bandyopadhyay, I.T. Yeh & L.Z. Sun: Transforming Growth Factor-β Signaling in Prostate Stromal Cells Supports Prostate Carcinoma Growth by Up-regulating Stromal Genes Related to Tissue Remodeling. Cancer Res 67, 5737-5746 (2007) (Pubitemid 46985006)
20. Miettinen P.J, R. Ebner, A.R. Lopez & R. Derynck: TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 127, 2021-2036 (1994)
21. Brown K.A, M.E. Aakre, A.E. Gorska, J.O. Price, S.E. Eltom, J.A. Pietenpol & H.L. Moses: Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res 6, R215-R231 (2004)
22. Siegel P.M & J. Massague: Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3, 807-821 (2003)
23. Tang B, M. Vu, T. Booker, S.J. Santner, F.R. Miller, M.R. Anver & L.M. Wakefield: TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112, 1116-1124 (2003) (Pubitemid 38056326)
24. Nikki C, C. Anna, S. Yu, J. Alison & L.M. Harold: Enhanced Hepatocyte Growth Factor Signaling by Type II Transforming Growth Factor-B Receptor Knockout Fibroblasts Promotes Mammary Tumorigenesis. Cancer Res 67, 4869-4877 (2007)
25. Polak M.E, N.J. Borthwick, F.G. Gabriel, P. Johnson, B. Higgins, J. Hurren, D. McCormick, M.J. Jager & I.A. Cree: Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 96, 1879-1887 (2007) (Pubitemid 46912012)
26. + regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 14, 85-89 (2003) (Pubitemid 36389522)
27. Zeng Z, X. Xu, Y. Zhang, J. Xing, J. Long, L. Gu, X. Wang, D. Sun, W. Ka, W. Yao, Z. Wen & S. Chien: Tumor-Derived Factors Impaired Motility and Immune Functions of Dendritic Cells Through Derangement of Biophysical Characteristics and Reorganization of Cytoskeleton. Cell Motil Cytoskeleton 64,186-198 (2007)
28. Nazareth M.R, L. Broderick, M.R. Simpson-Abelson, R.J. Jr. Kelleher, S.J. Yokota & R.B. Bankert: Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells. J Immunol 178, 5552-5562 (2007) (Pubitemid 46674350)
29. Michelle K, C. Elizabeth, M.B. Karen, S. Laurie & M.M. Andrea: Metastatic breast cancer induces anosteoblast inflammatory response. Exp Cell Res Epub ahead of print (2007)
30. Laurent B, L.W. Lisa, M.C. John & A.G. Theresa: The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Lett 246, 230-236 (2007)
31. Scott L.K, D. Michele, B. Kelly & L.W. Kristy: TGF-β Promotes the Establishment of Renal Cell Carcinoma Bone Metastasis. J Bone Miner Res 22, 37-44 (2007)
32. Isufi I, M. Seetharam, L. Zhou, D. Sohal, J. Opalinska, P. Pahanish, & A. Verma: Transforming growth factor-beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res 27, 543-552 (2007) (Pubitemid 47122713)
33. Daniel G.S, B. Brian & L.M. Harold: A Delicate Balance: TGF-β and the Tumor Microenvironment. J Cell Biochem 101, 851-861 (2007)
34. Pikarsky E, R.M. Porat, I. Stein, R. Abramovitch, S. Amit, S. Kasem, E. Gutkovich-Pyest, S. Urieli-Shoval, E. Galun & Y. Ben-Neriah: NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461-466 (2004) (Pubitemid 39329586)
35. Stathopoulos G.T, A. Kollintza, C. Moschos, I. Psallidas, T.P. Sherrill, E.N. Pitsinos, S. Vassiliou, M. Karatza, S.A. Papiris, D. Graf, D. Orphanidou, R.W. Light, C. Roussos, T.S. Blackwell & I. Kalomenidis: TumorNecrosis Factor-α Promotes Malignant Pleural Effusion. Cancer Res 67, 9825-9834 (2007) (Pubitemid 47621230)
36. Ren, D.H, E. Mayhew, C. Hay, H. Li, H. Alizadeh, & J.Y. Niederkorn: Uveal melanoma expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and susceptibility to TRAIL-induced apoptosis. Invest Ophthalmol Vis Sci 45, 1162-1168 (2004) (Pubitemid 38869022)
37. Jack D.B & D.S. Robert: Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes Curr Opin Immunol 19, 203-208 (2007)
38. Ingrid H, S. Peter & W.B. Markus: On the TRAIL to Therapeutic Intervention in Liver Disease. Hepatology 46, 266-274 (2007)
39. Ishiyama K, H. Ohdan, M. Ohira, H. Mitsuta, K. Arihiro & T. Asahara: Difference in cytotoxicity againsthepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 43, 362-372 (2006)
40. Müerköster S, K. Wegehenkel, A. Arlt, M. Witt, B. Sipos, M.L. Kruse, T. Sebens, G. Klöppel, H. Kalthoff, U.R. Fölsch & H. Schäfer: Tumor stroma interactions induce chemoresistance in pancreatic ductalcarcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 64, 1331-1337 (2004) (Pubitemid 38235601)
41. Bhowmick N.A, E.G. Neilson & H.L. Moses: Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337 (2004) (Pubitemid 39551661)
42. Neville-Webbe H.L, N.A. Cross, C.L. Eaton, R. Nyambo, C.A. Evans, R.E. Coleman & I. Holen: Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 86, 269-279 (2004) (Pubitemid 39070969)
43. Blankenstein T: The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 17, 180-186 (2005) (Pubitemid 40343106)
44. Zhong H, A.M. De Marzo, E. Laughner, M. Lim, D.A. Hilton, D. Zagzag, P. Buechler, W.B. Isaacs, G.L. Semenza & J.W. Simons: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59, 5830-5835 (1999)
45. Kim K.U, S.M. Wilson, K.S. Abayasiriwardana, R. Collins, L. Fjellbirkeland, Z. Xu, D.M. Jablons, S.L.Nishimura & V.C. Broaddus: A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 33, 541-548 (2005) (Pubitemid 41753129)
46. Trauzold A, D. Siegmund, B. Schniewind, B. Sipos, J. Egberts, D. Zorenkov, D. Emme, C. Röder, H. Kalthoff & H. Wajant: TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25, 7434-7439 (2006) (Pubitemid 44853434)
47. Mazzone M & P.M. Comoglio: The Met pathway: master switch and drug target in cancer progression. FASEBJ 20, 1611-1621 (2006) (Pubitemid 44943798)
48. Matsumoto K & T. Nakamura: Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 119, 477-483 (2006) (Pubitemid 43955698)
49. Stuelten C.H, S. DaCosta-Byfield, P.R. Arany, T.S. Karpova, W.G. Steler-Stevenson & A.B. Roberts: Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-β. J Cell Sci 118, 2143-2153 (2005) (Pubitemid 40872837)
50. Zhou Y.H & A.S.T. Wong: Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 147, 2557-2566 (2006)
51. Kang H, G. Watkins, C. Parr, A. Douglas-Jones, R.E. Mansel & W.G. Jiang: Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 7, R402-R410 (2005)
52. Barbero S, R. Bonavia, A. Bajetto, C. Porcile, P. Pirani, J.L. Ravetti, G.L. Zona, R. Spaziante, T. Florio & G. Schettini: Stromal cell-derived factor 1α stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 63, 1969-1974 (2003) (Pubitemid 36460865)
53. Marchesi F, P. Monti, B.E. Leone, A. Zerbi, A. Vecchi, L. Piemonti, A. Mantovani & P. Allavena: Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 64, 8420-8427 (2004) (Pubitemid 39491782)
54. Sun Y.X, J. Wang, C.E. Shelburne, D.E. Lopatin, A.M. Chinnaiyan, M.A. Rubin, K.J. Pienta & R.S. Taichman: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCα) in vivo. J Cell Biochem 89, 462-473 (2003) (Pubitemid 36648768)
55. Hwang J.H, H.K. Chung, D.W. Kim, E.S. Hwang, J.M. Suh, H. Kim, K.H. You, O.Y. Kwon, H.K. Ro, D.Y. Jo & M. Shong: CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88, 408-416 (2003) (Pubitemid 36115196)
56. Ceradini D.J, A.R. Kulkarni, M.J. Callaghan, O.M. Tepper, N. Bastidas, M.E. Kleinman, J.M. Capla, R.D.Galiano, J.P. Levine & G.C. Gurtner: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10, 858-864 (2004) (Pubitemid 39070860)
57. Sonoda Y, T. Ozawa, K.D. Aldape, D.F. Deen, M.S. Berger & R.O. Pieper: Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 61, 6674-6678 (2001) (Pubitemid 32896484)
58. Hall J.M & K.S. Korach: Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 17, 792-803 (2003) (Pubitemid 36539573)
59. Helbig G, K.W. Christopherson, P. Bhat-Nakshatri, S. Kumar, H. Kishimoto, K.D. Miller, H.E. Broxmeyer & H.Nakshatri: NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278, 21631-21638 (2003) (Pubitemid 36792563)
60. Kryczek I, A. Lange, P. Mottram, X. Alvarez, P. Cheng, M. Hogan, L. Moons, S. Wei, L. Zou, V. Machelon,D. Emilie, M. Terrassa, A. Lackner, T.J. Curiel, P. Carmeliet & W. Zou: CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 65, 465-472 (2005)
61. Curiel T.J, P. Cheng, P. Mottram, X. Alvarez, L. Moons, M. Evdemon-Hogan, S. Wei, L. Zou, I. Kryczek, G. Hoyle, A. Lackner, P. Carmeliet & W. Zou: Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 64, 5535-5538 (2004) (Pubitemid 39095544)
62. Staller P, J. Sulitkova, J. Lisztwan, H. Moch, E.J. Oakeley & W. Krek: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425, 307-311 (2003) (Pubitemid 37158407)
63. Muller A, B. Homey, H. Soto, N. Ge, D. Catron, M.E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S.N. Wagner, J.L. Barrera, A. Mohar, E. Verastegui & A. Zlotnik: Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001) (Pubitemid 32225831)
64. Liang Z, Y. Yoon, J. Votaw, M.M. Goodman, L. Williams & H. Shim: Silencing of CXCR4 blocks breast cancermetastasis. Cancer Res 65, 967-971 (2005) (Pubitemid 40216458)
65. Orimo A, P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V.J. Carey, A.L. Richardson & R.A. Weinberg: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005) (Pubitemid 40692295)
66. Kucia M, R. Reca, K. Miekus, J. Wanzeck, W. Wojakowski, A. Janowska-Wieczorek, J. Ratajczak & M.Z. Ratajczak: Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23, 879-894 (2005) (Pubitemid 41170944)
67. Zou L, B. Barnett, H. Safah, V.F. Larussa, M. Evdemon-Hogan, P. Mottram, S. Wei, O. David, T.J.Curiel & W. Zou: Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 64, 8451-8455 (2004) (Pubitemid 39491786)
68. Dunn G.P, A.T. Bruce, K.C. Sheehan, V. Shankaran, R. Uppaluri, J.D. Bui, M.S. Diamond, C.M. Koebel, C. Arthur, J.M. White & R.D. Schreiber: A critical function for type I interferons in cancer immunoediting. Nat Immunol 6, 722-729 (2005) (Pubitemid 41716746)
69. Ruszczak Z, M. Detmar, E. Imcke & C.E. Orfanos: Effects of rIFN-alpha, beta, and gamma on themorphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro. J Invest Dermatol 95, 693-699 (1990)
70. Fukuzawa K & T. Horikoshi: Inhibitory effect of human fibroblast interferon (HuIFN-β) on the growth andinvasive potential of cultured human melanoma cells in vitro. Br J Dermatol 126, 324-330 (1992)
71. Fabra A, M. Nakajima, C.D. Bucana & I.J. Fidler: Modulation of the invasive phenotype of human colon carcinoma cells by organ-specific fibroblasts of nude mice. Differentiation 52, 101-110 (1997)
72. Isaiah J.F: Regulation of Neoplastic Angiogenesis. J Natl Cancer Inst Monogr 28, 10-14 (2000)
73. Yang D, T.J. Stewart, K.K. Smith, D. Georgi, S.I. Abrams & K. Liu: Downregulation of IFN-R in association with loss of Fas function is linked to tumor progression. Int J Cancer 122, 350-362 (2008) (Pubitemid 350234721)
74. Slaton J.W, P. Perrotte, K. Inoue, C.P.N. Dinney & I.J. Fidler: Interferon-alpha-mediated downregulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of dose and schedule. Clin Cancer Res 5, 2726-2734 (1999) (Pubitemid 29493945)
75. Bielenberg D.R, I.J. Fidler & C.D. Bucana: Constitutive expression of interferon-beta in differentiated epithelial cells exposed to environmental stimuli. Cancer Biother Radiopharmaceut 13, 375-382 (1998) (Pubitemid 29011310)
76. Lewis A.M, S. Varghese, H. Xu & H.R. Alexander: Interleukin-1 and cancer progression: the emerging role ofinterleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 4, 48 (2006)
77. Krelin Y, E. Voronov, S. Dotan, M. Elkabets, E. Reich, M. Fogel, M. Huszar, Y. Iwakura, S. Segal, C.A. Dinarello & R.N. Apte: Interleukin-1β-Driven Inflammation Promotes the Development and Invasiveness of ChemicalCarcinogen-Induced Tumors. Cancer Res 67, 1062-1071 (2007)
78. Song X, Y. Krelin, T. Dvorkin, O. Bjorkdahl, S. Segal, C.A. Dinarello, E. Voronov & R.N. Apte: CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1{β}-secreting cells. J Immunol 175, 8200-8208 (2005) (Pubitemid 41798384)
79. Whiteside T.L: Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16, 3-15 (2006) (Pubitemid 43139705)
80. Watford W.T, B.D. Hissong, J.H. Bream, Y. Kanno, L. Muul & J.J. O'Shea: Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 202, 139-156 (2004) (Pubitemid 39576910)
81. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev 3, 133-146 (2003) (Pubitemid 37328691)
82. Hu J, X. Yuan, M. L. Belladonna, J. M. Ong, S. Wachsmann-Hogiu, D. L. Farkas, K. L. Black & J. S. Yu: Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 66, 8887-8896 (2006) (Pubitemid 44449207)
83. Langowski J.L, X. Zhang, L. Wu, J.D. Mattson, T. Chen, K. Smith, B. Basham, T. McClanahan, R.A. Kastelein & M. Oft: IL-23 promotes tumour incidence and growth. Nature 442, 461-465 (2006) (Pubitemid 44264796)
84. Langrish C.L, Y. Chen, W.M. Blumenschein, J. Mattson, B. Basham, J.D. Sedgwick, T. McClanahan, R.A. Kastelein & D.J. Cua: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201, 233-240 (2005) (Pubitemid 40189432)
85. Kolls J.K & A. Linden: Interleukin-17 family members and inflammation. Immunity 21, 467-476 (2004) (Pubitemid 39370503)
86. Tato C.M. & J.J. O'Shea: Immunology: what does it mean to be just 17 Nature 441, 166-168 (2006)
87. Bettelli E, Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka, H.L. Weiner & V.K. Kuchroo: Reciprocaldevelopmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006)
88. Numasaki M, M. Watanabe, T. Suzuki, H. Takahashi, A. Nakamura, F. McAllister, T. Hishinuma, J. Goto, M.T. Lotze, J.K. Kolls & H. Sasaki: IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175, 6177-6189 (2005) (Pubitemid 41508106)
89. Numasaki M, J. Fukushi, M. Ono, S.K. Narula, P.J. Zavodny, T. Kudo, P.D. Robbins, H. Tahara & M.T. Lotze: Interleukin-17 promotes angiogenesis and tumor growth. Blood 101, 2620-2627 (2003) (Pubitemid 36857622)
90. Numasaki M, M.T. Lotze & H. Sasaki: Interleukin-17 augments tumor necrosis factor-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 93, 39-43 (2004) (Pubitemid 38591518)
91. Chan J.R, W. Blumenschein, E. Murphy, C. Diveu, M. Wiekowski, S. Abbondanzo, L. Lucian, R. Geissler, S. Brodie, A.B. Kimball, D.M. Gorman, K. Smith, R. de Waal Malefyt, R.A. Kastelein, T.K. McClanahan & E.P. Bowman: IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203, 2577-2587 (2006) (Pubitemid 44833335)
92. Langowski, A.R.K & O. Martin: Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol28, 207-212 (2007)
93. Kryczek I, S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang & W. Zou: Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment. J Immunol 178, 6730-6733 (2007) (Pubitemid 46847396)
94. Ishihara K & T. Hirano: IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13,357-368 (2002)
95. Osborne J, P.S. Moore & Y. Chang: KSHV encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol 60, 921-927 (1999) (Pubitemid 29518115)
96. Bommert K, R.C. Bargou & T. Stuhmer: Signaling and survival pathways in multiple myeloma. Eur J Cancer 42, 1574-1580 (2006) (Pubitemid 44118772)
97. Cozen W, P.S. Gill, S.A. Ingles, R. Masood, O. Martínez-Maza, M.G. Cockburn, W.J. Gauderman, M.C. Pike, L. Bernstein, B.N. Nathwani, M.T. Salam, K.L. Danley, W. Wang, J. Gage, S. Gundell-Miller & T.M. Mack: IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 103, 3216-3221 (2004) (Pubitemid 38451701)
98. Hideshima T, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N.C. Munshi, D. Chauhan, P.G. Richardson & K.C. Anderson: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107, 4053-4062 (2006) (Pubitemid 43726814)
99. Corre J, K. Mahtouk, M. Attal, M. Gadelorge, A. Huynh, S. Fleury-Cappellesso, C. Danho, P. Laharrague, B. Klein, T. Rème & P. Bourin: Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21, 1079-1088 (2007) (Pubitemid 46672085)
100. Arnulf B, S. Lecourt, J. Soulier, B. Ternaux, M.N. Lacassagne, A. Crinquette, J. Dessoly, A.K. Sciaini, M.Benbunan, C. Chomienne, J.P. Fermand, J.P. Marolleau & J. Larghero: Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21, 158-163 (2007) (Pubitemid 44921847)
101. Mitsiades C.S, N. Mitsiades, N.C. Munshi & K.C. Anderson: Focus on multiple myeloma. Cancer Cell 6, 439-444 (2004) (Pubitemid 39469979)
102. Hideshima T, P.L. Bergsagel, W.M. Kuehl & K.C. Anderson: Advances in biology of multiple myeloma: Clinical applications. Blood 104, 607-618 (2004) (Pubitemid 38970551)
103. Constantine S.M, S.M. Nicholas, G.R. Paul, C.M. Nikhil & C.A. Kenneth: Multiple Myeloma: A Prototypic Disease Model for the Characterization and Therapeutic Targeting of Interactions Between Tumor Cells and Their Local Microenvironment. J Cell Biochem 101, 950-968 (2007)
104. Hsin-Hsin P, L. Shile, J.H. Andrew & D. Cheng: Regulation of interleukin-8 expression in melanomastimulated neutrophil inflammatory response. Exp Cell Res 313, 551-559 (2007)
105. Shile L, S. Arati, P. Hsin-Hsin, R. Gavin & D. Cheng: Targeting Mutant (V600E) B-Raf in Melanoma Interrupts Immunoediting of Leukocyte Functions and Melanoma Extravasation. Cancer Res 67, 5814-5820 (2007)
106. Solomayer E.F, I.J. Diel, G.C. Meyberg, C. Gollan & G. Bastert: Metastatic breast cancer: clinical course,prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59, 271-278 (2000) (Pubitemid 30243049)
107. Hoentjen F, R.B. Sartor, M. Ozaki & C. Jobin: STAT3 regulates NF-κB recruitment to the IL-12p40 promoter indendritic cells. Blood 105, 689-696 (2005) (Pubitemid 40070754)
108. Kohno T, H. Mizukami, M. Suzuki, Y. Saga, Y. Takei, M. Shimpo, T. Matsushita, T. Okada, Y. Hanazono, A. Kume, I. Sato & K. Ozawa: Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 63, 5091-5094 (2003) (Pubitemid 37022649)
109. Huang S, S.E. Ullrich & M. Bar-Eli: Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 19, 697-703 (1999) (Pubitemid 29379811)
110. Sredni B, M. Weil, G. Khomenok, I. Lebenthal, S. Teitz, Y. Mardor, Z. Ram, A. Orenstein, A. Kershenovich, S. Michowiz, Y.I. Cohen, Z.H. Rappaport, I. Freidkin, M. Albeck, D.L. Longo & Y. Kalechman: Ammonium trichloro (dioxoethylene-o,o') tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin-10 autocrine loop. Cancer Res 64, 1843-1852 (2004) (Pubitemid 38428710)
111. Alas S, C. Emmanouilides & B. Bonavida: Inhibition of interleukin-10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7, 709-723 (2001) (Pubitemid 32707998)
112. Ogden C.A, J.D. Pound, B.K. Batth, S. Owens, I. Johannessen, K. Wood & C.D. Gregory: Enhancedapoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J Immunol 174, 3015-3023 (2005) (Pubitemid 40279722)
113. García-Hernández M.L, R. Hernández-Pando, P. Gariglio & J. Berumen: Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology 105, 231-243 (2002) (Pubitemid 34146690)
114. Mocellin S, F.M. Marincola & H.A. Young: Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78, 1043-1051 (2005) (Pubitemid 41572467)
115. Sheu B.C, R.H. Lin, H.C. Lien, H.N. Ho, M.S. Hsu & S.C. Huang: Predominant Th2/Tc2 polarity of tumorinfiltrating lymphocytes in human cervical cancer. J Immunol 167, 2972-2978 (2001)
116. Battaglia M, S. Gregori, R. Bacchetta & M.G. Roncarolo: Tr1 cells: from discovery to their clinicalapplication. Semin Immunol 18, 120-127 (2006) (Pubitemid 43248740)
117. + Tr cells. Blood 105, 1162-1169 (2005) (Pubitemid 40170889)
118. + T lymphocytes. Blood Epub ahead of print (2007)
119. Malek T.R & A.L. Bayer: Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4, 665-674(2004) (Pubitemid 39223073)
120. Bergmann C, L. Strauss, R. Zeidler, S. Lang & T.L. Whiteside: Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother 56, 1429-1442 (2007) (Pubitemid 47024702)
121. Fontenot J.D, J.P. Rasmussen, M.A. Gavin & A.Y. Rudensky: A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6, 1142-1151 (2005) (Pubitemid 41541792)
122. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6, 345-352 (2005) (Pubitemid 41716771)
123. + regulatory T cells and for expansion of these cells. J Immunol 178, 2018-2027 (2007) (Pubitemid 46233398)
124. + regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol 19, 785-799 (2007) (Pubitemid 47073268)
125. Kuniyasu H, H. Ohmori, T. Sasaki, T. Sasahira, K. Yoshida, Y. Kitadai & I.J. Fidler: Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res 9, 4802-4810 (2003) (Pubitemid 37323283)
126. Tinhofer I, I. Marschitz, T. Henn, A. Egle & R. Greil: Expression of functional interleukin-15 receptor and autocrineproduction of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 95, 610-618 (2000) (Pubitemid 30041677)
127. Sheu B.C, R.H. Lin, H.N. Ho & S.C. Huang: Downregulation of CD25 expression on the surface of activated tumor-infiltrating lymphocytes in human cervical carcinoma. Hum Immunol 56, 39-48 (1997)
128. Chiou S.H., B.C. Sheu, W.C. Chang, S.C. Huang & H.N. Ho: Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol 67, 35-50 (2005)
129. Sheu B.C., S.M. Hsu, H.N. No, H.C. Lien, S.C. Huang & R.H. Lin: A novel role of metalloproteinase in cancermediated immunosuppression. Cancer Res 61, 237-242 (2001)
130. Sheu B.C., H.C. Lien, H.N. Ho, H.H. Lin, S.N. Chow, S.C. Huang & S.M. Hsu : Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 63, 6537-6542 (2003)
131. He, Y.G, E. Mayhew, J. Mellon & J.Y. Niederkorn: Expression and possible function of IL-2 and IL-15 receptorson human uveal melanoma cells. Invest Ophthalmol Vis Sci 45, 4240-4246 (2004) (Pubitemid 39564645)
132. Barzegar C, R. Meazza, R. Pereno, C. Pottin-Clemenceau, M. Scudeletti, D. Brouty-Boyé, C. Doucet, Y. Taoufik, J. Ritz, C. Musselli, Z. Mishal, C. Jasmin, F. Indiveri, S. Ferrini & B. Azzarone: IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene 16, 2503-2512 (1998) (Pubitemid 28258582)
133. Sheu B.C., S.M. Hsu, H.N. Ho, R.H. Lin, P.L. Torng & S.C. Huang: Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma. Cancer 86, 1537-1543 (1999)
134. Sheu B.C., S.H. Chiou, H.H. Lin, S.N. Chow, S.C. Huang, H.N. Ho & S.M. Hsu: Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8 (+) T lymphocytes in human cervical carcinoma. Cancer Res 65, 2921-2929 (2005)
135. Chang W.C., S.C. Huang, P.L. Torng, D.Y. Chang, W.C. Hsu, S.H. Chiou, S.N. Chow & B.C. Sheu : Expression of inhibitory natural killer receptors on tumor-infiltrating CD8 (+) T lymphocyte lineage in human endometrial carcinoma. Int J Gynecol Cancer 15, 1073-1080 (2005)
136. Sheu B.C., W.C. Chang, H.H. Lin, S.N. Chow & S.C. Huang: Immune concept of human papillomaviruses and related antigens in local cancer milieu of
137. Hsiao Y.W, K.W. Liao, T.F. Chung, C.H. Liu, C.D. Hsu & R.M. Chu: Interactions of host IL-6 and IFN-gammaand cancer-derived TGF-beta1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol Immunother (2008) (Epub ahead of print)
138. + T cells for adoptive immunotherapy. Blood (2008) (Epub ahead of print)
139. Shashkova E.V, M.N. Kuppuswamy, W.S.M. Wold & K. Doronin: Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther 15, 61-72 (2008)